India launches Viral Hepatitis Control Program as domestic drugmakers challenge patents
Ahead of World Hepatitis Day on July 28, the Indian government is to give away free antiviral for hepatitis C to tackle liver cancer. With $87.50 million approved for the current financial year, the government is all set to launch an ambitious National Viral Hepatitis Control Program, reports The Pharma Letter’s India correspondent.
The hepatitis virus is responsible for a large proportion of liver cancer and cirrhosis cases in the country. Hepatitis A is responsible for 10%-30% of acute hepatitis and 5%-15% of acute liver failure cases in India. The E variant, on the other hand, accounts for 10%-40% of acute hepatitis and 15%- 45% of acute liver failure.
India is second to China in terms of number of chronic Hepatitis B infections, the most serious and contagious type of viral Hepatitis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze